PolyMedix Inc. has received a two-year, $923,080 grant to continue work on a compound that would aid in blood coagulation in patients immediately after they have undergone surgery and in bleeding emergencies.

This follow-up to a $100,000 Phase I grant received by PolyMedix in 2007 is expected to pay for four scientific staff at the Radnor biotechnology firm.

The grant is being sponsored by the National Institutes of Health.

The company's lead coagulation compound is in Phase I clinical trials.